[Clinical experiences with a gestodene containing oral contraceptive (femoden)].
In order to reduce the side-effects (blood-lipid alterations, androgen effects etc.) new gestogens were introduced, while the ethinyl-estradiol component of the pill was unchanged. Authors report about clinical trial on monophasic oral contraceptive containing 0.030 mg ethinyl-estradiol and 0.075 mg gestodene. In a follow up of 92 women, in 1740 cycles no pregnancy and no cardivascular or thromboembolic complication was observed. The frequency of bleeding disorders was below 10% already in the first cycle. The quantity of withdrawal bleeding, as well the frequency of breakthrough bleeding and spotting decreased during the treatment. Significant alteration in body weight or blood pressure did not occur. Femoden containing third generation gestogen has an excellent cycle control and good patient compliance.
Gimes
G
G
Semmelweis Orvostudományi Egyetem, II. sz. Szülészeti és Nógyógyászati Klinika, Budapest.
Valent
S
S
D000328:Adult; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects; D003280:Contraceptives, Oral, Synthetic / Q000009:adverse effects; D004997:Ethinyl Estradiol / Q000009:adverse effects; D005260:Female; D006801:Humans; D008597:Menstrual Cycle; D009652:Norpregnenes / Q000009:adverse effects; D011247:Pregnancy
D003277:Contraceptives, Oral, Combined; D003280:Contraceptives, Oral, Synthetic; D009652:Norpregnenes; C033273:Gestodene; D004997:Ethinyl Estradiol